A Translocator Protein Ligand PK11195 Shows Antigrowth Activity in Human Choriocarcinoma Cells

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2012 Apr 25

PMID 22528948

Authors

Noriyuki Takai

Naoko Kira

Terukazu Ishii

Toshie Yoshida

Masakazu Nishida

Yoshihiro Nishida

Kaei Nasu

Masayuki Takano

Haruna Midori

Satoko Koga

Hisashi Narahara

Affiliations

Soon will be listed here.

Abstract

The potential anticancer agent 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195), a translocator protein ligand (initially described as a ligand for the peripheral benzodiazepine receptor), induces apoptosis in some lines of human tumor cells. We investigated the effect of PK11195 in the choriocarcinoma cell line, BeWo. BeWo cells were treated with various concentrations of PK11195, and changes in cell growth, the cell cycle, apoptosis, and related parameters were examined. A WST-1 assay showed that BeWo cells were sensitive to the growth inhibitory effect of PK11195. In contrast, the nonsite selective ligand diazepam has a little effect on these cells. Cell cycle analysis indicated that exposure to PK11195 decreased the proportion of cells in the S phase and increased the proportion in the G0/G1 phases of the cell cycle. Induction of apoptosis was confirmed by Annexin V staining of externalized phosphatidylserine, by the loss of mitochondrial transmembrane potential, and by antibodies directed against histones from fragmented DNA. This induction occurred in conjunction with the altered expression of genes related to cell growth, malignant phenotype, and apoptosis. These results suggest that PK11195 may serve as a therapeutic agent for the treatment of choriocarcinoma.

References

de Jong D, Prins F, Mason D, Reed J, van Ommen G, Kluin P . Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res. 1994; 54(1):256-60. View

Chen Y, Kramer D, Diegelman P, Vujcic S, Porter C . Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001; 61(17):6437-44. View

Johnson D, Walker C . Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999; 39:295-312. DOI: 10.1146/annurev.pharmtox.39.1.295. View

Gonzalez-Polo R, Carvalho G, Braun T, Decaudin D, Fabre C, Larochette N . PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene. 2005; 24(51):7503-13. DOI: 10.1038/sj.onc.1208907. View

Hirsch T, Marzo I, Kroemer G . Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep. 1997; 17(1):67-76. DOI: 10.1023/a:1027339418683. View

Rimon G, Bazenet C, Philpott K, Rubin L . Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997; 48(6):563-70. DOI: 10.1002/(sici)1097-4547(19970615)48:6<563::aid-jnr9>3.0.co;2-8. View

Sutter A, Maaser K, Hopfner M, Barthel B, Grabowski P, Faiss S . Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer. 2002; 102(4):318-27. DOI: 10.1002/ijc.10724. View

Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H . Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002; 128(6):307-12. DOI: 10.1007/s00432-002-0328-3. View

Takai N, Desmond J, Kumagai T, Gui D, Said J, Whittaker S . Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res. 2004; 10(3):1141-9. DOI: 10.1158/1078-0432.ccr-03-0100. View

10.

Ly J, Grubb D, Lawen A . The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis. 2003; 8(2):115-28. DOI: 10.1023/a:1022945107762. View

11.

Jones W, Cardinale C, Lewis Jr J . Management of high-risk gestational trophoblastic disease--the Memorial Hospital experience. Int J Gynecol Cancer. 1997; 7(1):27-33. DOI: 10.1046/j.1525-1438.1997.00409.x. View

12.

Papadopoulos V, Baraldi M, Guilarte T, Knudsen T, Lacapere J, Lindemann P . Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006; 27(8):402-9. DOI: 10.1016/j.tips.2006.06.005. View

13.

Takai N, Ueda T, Nishida M, Nasu K, Narahara H . Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008; 21(5):637-43. View

14.

Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, Caron A . Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 2002; 62(5):1388-93. View

15.

Zoratti M, Szabo I . The mitochondrial permeability transition. Biochim Biophys Acta. 1995; 1241(2):139-76. DOI: 10.1016/0304-4157(95)00003-a. View

16.

Berkowitz R, Goldstein D, Bernstein M . Modified triple chemotherapy in the management of high-risk metastatic gestational trophoblastic tumors. Gynecol Oncol. 1984; 19(2):173-81. DOI: 10.1016/0090-8258(84)90177-x. View

17.

Ansseau M, von Frenckell R, Cerfontaine J, Papart P . Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology. Pharmacopsychiatry. 1991; 24(1):8-12. DOI: 10.1055/s-2007-1014425. View

18.

Ferry A, Jaillon P, Lecocq B, Lecocq V, Jozefczak C . Pharmacokinetics and effects on exercise heart rate of PK 11195 (52028 RP), an antagonist of peripheral benzodiazepine receptors, in healthy volunteers. Fundam Clin Pharmacol. 1989; 3(4):383-92. DOI: 10.1111/j.1472-8206.1989.tb00679.x. View

19.

Muscarella D, OBrien K, Lemley A, Bloom S . Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. Toxicol Sci. 2003; 74(1):66-73. DOI: 10.1093/toxsci/kfg052. View

20.

Surwit E, Hammond C . Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980; 55(5):565-70. View